The shorter terminal half-life of α-IL-6 mAb (T1/2 = 57h) versus α-IL-6R mAb (T1/2 = 223h), possibly due to isotype specific differences in glycosylation (Cobb, 2019) may help explain why giving α-IL-6 mAb early after infection provided the most observed clinical benefit. The gene discussed is IL6R; the disease is infection.